Literature DB >> 1318047

Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?

M A Giembycz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1318047     DOI： 10.1016/0006-2952(92)90160-k

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  24 in total

1.  Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.

Authors:  P G Bardin; M A Dorward; F C Lampe; B Franke; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

2.  Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

Authors:  J Cortijo; V Villagrasa; C Navarrete; C Sanz; L Berto; A Michel; P A Bonnet; E J Morcillo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 3.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 4.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 5.  Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

Authors:  I P Hall
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

6.  Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

Authors:  J E Souness; M E Villamil; L C Scott; A Tomkinson; M A Giembycz; D Raeburn
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.

Authors:  J Van Wauwe; F Aerts; H Walter; M de Boer
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

Review 9.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

Review 10.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.